Implantica AG (FRA:8IM1)
Germany flag Germany · Delayed Price · Currency is EUR
4.795
-0.030 (-0.62%)
At close: Dec 4, 2025

Implantica AG Company Description

Implantica AG engages in the research and distribution of medical implants in Switzerland.

The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease.

It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite.

In addition, the company develops UriControl, a hand pumped artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform.

Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for monitoring the expansion of the aneurysms.

The company was founded in 2015 and is based in Vaduz, Liechtenstein.

Implantica AG
Country Liechtenstein
Founded 2015
Industry Surgical and Medical Instruments and Apparatus
Employees 50
CEO Peter Forsell

Contact Details

Address:
Aeulestrasse 45
Vaduz, 9490
Liechtenstein
Website implantica.com

Stock Details

Ticker Symbol 8IM1
Exchange Frankfurt Stock Exchange
Fiscal Year January - December
Reporting Currency EUR
SIC Code 3841

Key Executives

Name Position
Peter Forsell Chief Executive Officer
Andreas Öhrnberg Chief Financial Officer